Statement of Deviation & Variation for the quarter ended 31st March 2026
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bajaj Healthcare filed its quarterly compliance statement confirming no deviation in the use of proceeds from a preferential issue. The company raised Rs. 204.97 Crores (slightly undersubscribed from the proposed Rs. 207 Crores) through equity shares and convertible warrants. During Q4 FY2026, the company received Rs. 52.71 Crores upon exercise of conversion options by warrant holders. Fund utilization stands at Rs. 173 Crores: Rs. 150 Crores fully deployed for loan repayment, Rs. 3.16 Crores of Rs. 35 Crores allocated for capital expenditure (significant underutilization), and Rs. 19.84 Crores for general corporate purposes. CARE Ratings is the monitoring agency.
No deviation means regulatory compliance is met. The significant underutilization of capital expenditure funds (Rs. 3.16 Crores vs Rs. 35 Crores allocated) may indicate delayed capex plans or strategic reallocation, warranting monitoring. The promoter's warrant conversion demonstrates confidence.